LOS ANGELES–(BUSINESS WIRE)–$MESO #MESO—The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mesoblast Limited (“Mesoblast” or “the Company”) (NASDAQ: MESO) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. The FDA released briefing materials for the August 13, 2020, meeting of the Oncologic Drugs Advisory Committee on August 11, 2020. The meeting was to discuss Mesoblast’s marketing application for Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft-versus-host disease in pediatric patients. According to the FDA briefing documents, it was “unclear” if the study results are “relevant” to the proposed indication. Based on this news, shares of Mesoblast fell by nearly 35% on August 11.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at firstname.lastname@example.org.
The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.